Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy.

In conclusion, monitoring LFS patients with total-body photography and dermoscopy may be useful to detect early melanoma. PMID: 28218344 [PubMed - as supplied by publisher]
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research

Related Links:

Yicheng Ni Cancer remains a major cause of death globally. Given its relapsing and fatal features, curing cancer seems to be something hardly possible for the majority of patients. In view of the development in cancer therapies, this article summarizes currently available cancer therapeutics and cure potential by cancer type and stage at diagnosis, based on literature and database reviews. Currently common cancer therapeutics include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, treatment with curative intent by these methods are mainly eligible for patients with localized diseas...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Contributors : Pakavarin Louphrasitthiphol ; Colin R GodingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe MITF and SOX10 transcription factors regulate the expression of genes important for melanoma proliferation, invasion and metastasis. Despite growing evidence of the contribution of long non-coding RNAs (lncRNAs) in melanoma and other cancers, their functions within MITF-SOX10 transcriptional programmes is poorly investigated. Here, we identify 245 candidate melanoma associated lncRNAs whose loci are co-occupied by MITF-SOX10 and are enriched at active enhancer-like regions. W...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
AbstractNivolumab is a fully human monoclonal antibody that inhibits programmed cell death ‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐small cell lung cancer, renal cell carcinoma, or small cell lung cancer who rec eived nivolumab as monotherapy or in combination with ipilimumab or chemotherapy across 25 clinical studies. Nivolumab CL was similar across the tumor types examined; CL was higher for ipilimumab 1 mg/kg every 6 weeks (by 17%) and 3 mg/kg...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
AbstractIpilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time ‐varying clearance (CL) was assessed by a population pharmacokinetics (PPK) model developed using statistically significant covariates identified in a previous PPK analysis plus additional covariates. Data from 3,411 patients who received ipilimumab 0.3–10 mg/kg alone or in combination with niv olumab in 16 clinical trials were analyzed. Ipilimumab CL decreased over time; the ch...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
AbstractNivolumab is a fully human monoclonal antibody that inhibits programmed cell death ‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐small cell lung cancer, renal cell carcinoma, or small cell lung cancer who rec eived nivolumab as monotherapy or in combination with ipilimumab or chemotherapy across 25 clinical studies. Nivolumab CL was similar across the tumor types examined; CL was higher for ipilimumab 1 mg/kg every 6 weeks (by 17%) and 3 mg/kg...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
AbstractIpilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time ‐varying clearance (CL) was assessed by a population pharmacokinetics (PPK) model developed using statistically significant covariates identified in a previous PPK analysis plus additional covariates. Data from 3,411 patients who received ipilimumab 0.3–10 mg/kg alone or in combination with niv olumab in 16 clinical trials were analyzed. Ipilimumab CL decreased over time; the ch...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
Publication date: Available online 8 November 2019Source: Artificial Intelligence in MedicineAuthor(s): Ni Zhang, Yi-Xin Cai, Yong-Yong Wang, Yi-Tao Tian, Xiao-Li Wang, Benjamin BadamiAbstractEarly detection of skin cancer is very important and can prevent some skin cancers, such as focal cell carcinoma and melanoma. Although there are several reasons that have bad impacts on the detection precision. Recently, the utilization of image processing and machine vision in medical applications is increasing. In this paper, a new image processing based method has been proposed for the early detection of skin cancer. The method ut...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Conditions:   Solid Tumor;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Triple Negative Breast Cancer;   Small Cell Lung Cancer;   Metastatic Breast Cancer;   Malignant Melanoma;   Non Small Cell Lung Cancer;   Urothelial Carcinoma Interventions:   Drug: ZN-c3;   Drug: Talazoparib;   Drug: Pembrolizumab Sponsors:   K-Group Beta;   IQVIA Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Solid Tumors;   NSCLC;   Bladder Cancer;   HNSCC;   Renal Cancer;   Melanoma;   Anal Cancer;   Colorectal Cancer;   Cholangiocarcinoma;   Gastric Cancer;   Hepatocellular Carcinoma Interventions:   Drug: Continue PD-1/PD-L1 Inhibitors treatment;   Other: Discontinue PD-1/PD-L1-1 inhibitor Sponsor:   Antoinette J Wozniak Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Solid Tumor;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Triple Negative Breast Cancer;   Small Cell Lung Cancer;   Metastatic Breast Cancer;   Malignant Melanoma;   Non Small Cell Lung Cancer;   Urothelial Carcinoma Interventions:   Drug: ZN-c3;   Drug: Talazoparib;   Drug: Pembrolizumab Sponsors:   K-Group Beta;   IQVIA Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Dermatology | Genetics | Melanoma | Skin Cancer | Study